Literature DB >> 31486487

Preliminary results indicate increased expression of miR-184 in patients with renal carcinoma.

J Yang1, C-C Lai, Z-M Xian, W-Q Wang, B-L Xu.   

Abstract

OBJECTIVE: Renal carcinoma is the second most common cancer in the urinary system with an increasing trend. The major treatment for renal carcinoma is surgery, which results in unfavorable prognosis at times. As a tissue-specific marker for tumor, microRNA (miR) exerts its functions via facilitating oncogenic gene expression or suppressing tumor suppressor gene. MiR-184 is known to be abnormally expressed in various tumors. There are few studies about the lack of miR-184 expression in renal carcinoma. PATIENTS AND METHODS: Real time-Polymerase Chain Reaction (PCR) was used to measure the expression of miR-184 in 38 renal carcinoma and adjacent tissues. The in vitro cultured renal carcinoma cell line ACHN was transfected with miR-184 mimic or inhibitor. The expression of miR-184 was measured by real time-PCR, and the cell proliferation was measured by MTT assay. The cell colony formation was examined, and the cell invasion potency was assessed by transwell assay. The apoptotic activity was measured by flow cytometry, and the Western blot detected protein expression change of β-catenin/TCF3 pathway.
RESULTS: Compared to tumor-adjacent tissues, miR-184 and β-catenin/TCF3 showed an elevated expression in renal carcinoma tissues which were further increased with elevated RC stages (p<0.05). The transfection of miR-184 mimic into ACHN cells increased its expression, enhanced ACHN cell proliferation, colony formation, inhibited apoptosis, promoted tumor cell invasion, and increased the expression of β-catenin and TCF4 proteins (p<0.05 compared to NC control group).
CONCLUSIONS: MiR-184 is up-regulated in renal carcinoma tissues. The downregulation of miR-184 in renal carcinoma cells could facilitate cell apoptosis and inhibited tumor proliferation or invasion possibly via modulating β-catenin/TCF4 pathway.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31486487     DOI: 10.26355/eurrev_201908_18727

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Common pathways and functional profiles reveal underlying patterns in Breast, Kidney and Lung cancers.

Authors:  Sergio Romera-Giner; Zoraida Andreu Martínez; Francisco García-García; Marta R Hidalgo
Journal:  Biol Direct       Date:  2021-05-26       Impact factor: 4.540

2.  Aberrant expression profiles and bioinformatic analysis of CAF-derived exosomal miRNAs from three moderately differentiated supraglottic LSCC patients.

Authors:  Chunping Wu; Mei Wang; Qiang Huang; Yang Guo; Hongli Gong; Chunyan Hu; Liang Zhou
Journal:  J Clin Lab Anal       Date:  2021-11-17       Impact factor: 2.352

3.  Perioperative Circulating Tumor Cells (CTCs), MCTCs, and CTC-White Blood Cells Detected by a Size-Based Platform Predict Prognosis in Renal Cell Carcinoma.

Authors:  Zhenlong Wang; Peng Zhang; Yue Chong; Yuquan Xue; Xiaojie Yang; Hecheng Li; Li Wang; Yaping Zhang; Qi Chen; Zhaolun Li; Li Xue; HongLiang Li; Tie Chong
Journal:  Dis Markers       Date:  2021-10-25       Impact factor: 3.434

4.  miR-184-5p inhibits cell proliferation, invasion and predicts prognosis of clear cell renal cell carcinoma by targeting NUS1 dehydrodolichyl diphosphate synthase subunit: Results from large-scale comprehensive identification and validation.

Authors:  Wangrui Liu; Chunguang Ma; Hong Xu; Lijun Wang; Wenhao Xu; Hailiang Zhang; Zhisu Wang; Jun Li; Ji Zhang; Xigao Liu; Shuai Zhao; Tao Wang
Journal:  J Cancer       Date:  2022-02-21       Impact factor: 4.207

5.  DNA Methylation Influences miRNA Expression in Gonadotroph Pituitary Tumors.

Authors:  Joanna Boresowicz; Paulina Kober; Natalia Rusetska; Maria Maksymowicz; Agnieszka Paziewska; Michalina Dąbrowska; Natalia Zeber-Lubecka; Jacek Kunicki; Wiesław Bonicki; Jerzy Ostrowski; Janusz A Siedlecki; Mateusz Bujko
Journal:  Life (Basel)       Date:  2020-05-13

6.  Diagnostic Valuation of Serum miR-184 and miR-191 in Patients With Non-Small-Cell Lung Cancer.

Authors:  Hao Ding; Wei Wen; Qingqing Ding; Xin Zhao
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.